Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNT201 dose-escalation study in Dupuytren's contracture
ACTRN12624000664549Phase 2Recruiting
- Sponsor
- Connext
- Start
- Jul 2024
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of CNT201 in Dupuytren's contracture (5 cohorts), sponsored by Connext. Primary endpoint: Safety and tolerability of CNT201. Started Jul 2024; status: recruiting.
02
Drugs
CNT201
03
Conditions
Dupuytren's contracture
Beyond the preview
Go deeper on ACTRN12624000664549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000664549.